Zydus Cadila receives tentative approval from USFDA for Lenalidomide Capsules

Zydus Cadila has received tentative approval from the USFDA to market Lenalidomide Capsules in the strengths of 2.5 mg, 5 mg,10 mg, 15 mg, 20 mg, and 25 mg. (USRLD: Revlimid). Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Ltd. was last trading in BSE at Rs. 531.35 as compared to the previous close of Rs. 531.9. The total number of shares traded during the day was 324088 in over 6544 trades.

The stock hit an intraday high of Rs. 539.2 and intraday low of 527. The net turnover during the day was Rs. 172246616.

Source : Equity Bulls

Keywords